The purpose of the Investment is primarily to finance the company’s European phase 3 clinical trials, it states.

“We are very pleased to welcome Yangtian Pharma as a new strategic shareholder in OncoZenge. Together, we share the vision of bringing BupiZenge to a global market, and the millions of patients who deserve better pain relief during their cancer therapy. With their investment, we have secured the necessary funds for our registrational Phase 3 trial, which is currently in final scoping reviews with our intended European partner and licensee, Molteni Farmaceutici. These agreements, which together deliver on our partner strategy, position us to unlock the significant value creation potential we see in BupiZenge,” says Stian Kildal, CEO of OncoZenge.

The Investment is intended to be executed through four share issues corresponding to 10, 10, 30 and 50 percent of the Investment, estimated to be directed to the Investor during the first through the third quarter of 2025.

Part of Yangtian’s strategy of international cooperation with interesting pharmaceutical companies

“Our investment in Oncozenge is part of Yangtian’s strategy of international cooperation with interesting pharmaceutical companies. We are therefore excited to support Oncozenge when taking BupiZenge to international markets. We are also looking forward to exploring further pharmaceutical market opportunities such as in the United States and Asia. For the latter, and certainly in China, Yangtian have extensive expertise,” says Mr Zhang Zuo, Chaiman of Yangtian.